Workflow
AbbVie: Upgrading To 'Strong Buy' After Pullback
ABBVAbbVie(ABBV) Seeking Alpha·2024-11-22 20:10

As I was researching this article about AbbVie (NYSE: ABBV ), its price fell 16.8% due to negative data from two Phase 2 clinical trials evaluating the efficacy of emraclidine in treating schizophrenia. The stock fell in five consecutive sessions beforeWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs ...